Subject to shareholder and final board approval, Perkin-Elmer plans todistribute a new class of common stock intended to track the separate performance of the company's newly-created Celera Genomics business unit, which is focused on the discovery and distribution of genomic information.
Celera was formed through an alliance between P-E and Craig Venter, formerly president of The Institute for Genomic Research. Its mission is to become the definitive source of genomic and related biomedical information.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze